Who is sponsoring NCT00986960?

NCT00986960 is sponsored by University at Buffalo.

What drugs are being tested in NCT00986960?

Interventions in NCT00986960: repository corticotropin injection, Saline.

What condition does NCT00986960 study?

NCT00986960 studies Multiple Sclerosis.

Is NCT00986960 still recruiting?

NCT00986960 is currently withdrawn. Last updated 30 December 2020.

Last reviewed 2020-12-30 · How we verify

NCT00986960: ACTH

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effect of Pulsed ACTH add-on Therapy to Weekly Avonex on Remyelination and Neuroregeneration in Patients With Relapsing Remitting Multiple Sclerosis. A 1-year Placebo-controlled, Double-blinded, Randomized Follow-up Study

Withdrawn Phase 2 Last updated 30 December 2020

What this trial tests

Phase 2 trial testing repository corticotropin injection in Multiple Sclerosis. Withdrawn.

Timeline

1 December 2009

Primary endpoint
1 September 2010

1 December 2010

Quick facts

Lead sponsor	University at Buffalo
Phase	Phase 2
Status	Withdrawn
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Start date	1 December 2009
Primary completion	1 September 2010
Estimated completion	1 December 2010
Sites	1 location across United States

Drugs / interventions tested

repository corticotropin injection — full drug profile →
Saline

Conditions studied

Multiple Sclerosis — all drugs for Multiple Sclerosis →

Sponsor

University at Buffalo

Who can join

Adults 18 to 65, any sex, with Multiple Sclerosis. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

To define the effect of add-on pulsed IM ACTH vs. placebo to IFNβ-1a I.M. on a voxel-wise MTR dynamic mapping of the lesions and NABT in patients with RRMS
Time frame: 1 year
Effect of ACTH in MRI

Sponsor's own description

The purpose of this study is to evaluate whether the use of ACTH in addition to Avonex is effective in the treatment of relapsing remitting multiple sclerosis.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Remyelinating Drugs at a Crossroad: How to Improve Clinical Efficacy and Drug Screenings.
Al Jaf AIA, Peria S, Fabiano T, Ragnini-Wilson A. · · 2024 · cited 3× · PMID 39195216 · DOI 10.3390/cells13161326

Verify or expand the search:

Other trials of repository corticotropin injection

Trials testing the same drug.

NCT03398018 — Repository Corticotropin Injection in Keratoconjunctivitis Sicca · Phase 4 · withdrawn

Other recruiting trials for Multiple Sclerosis

Currently open trials in the same condition.

NCT07507084 — The Effect of Internal- or External-Focused Exercise Training, Administered in Conjunction With a Cognitive Task, on Wal · NA · recruiting
NCT07524231 — Evaluation of the Effects of Laughter Yoga · NA · recruiting
NCT07489794 — URINARY INCONTINENCE AND PELVIC FLOOR MUSCLE ACTIVITY IN MULTIPLE SCLEROSIS · recruiting
NCT07236684 — Identification of Factors Related to UI in Patients With MS and EMG Assessment of PFM Activity · recruiting
NCT07500727 — Skeletal Muscle Aging and Responsiveness in Aged People With MS · NA · recruiting

Other University at Buffalo trials

Trials by the same sponsor.

NCT06324630 — Implementation of Innovative Food Prescription Programs in Older Adults · NA · completed
NCT06681909 — University At Buffalo Campus Veggie Van Mobile Market · active not recruiting
NCT07088003 — Yoga as Mindful Movement: A Randomized Controlled Trial · NA · completed
NCT04557566 — ED Recovery Course Online RCT · NA · completed
NCT03920995 — Multi-center Database Registry to Study Thalamus Changes Using AI in MS · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT00986960 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University at Buffalo
Last refreshed: 30 December 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT00986960.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing